New agent may enhance effectiveness of radiotherapy

May 13, 2014 by Alison Barbuti, University of Manchester

Scientists from The University of Manchester – part of the Manchester Cancer Research Centre - have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumour growth.

There is increasing interest in using the body's own immune system to attack – a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits through a molecule known as toll-like receptor 7 (TLR7), a protein that recognises foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with and measured the effect on the primary tumour and the number of secondary tumours in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong from other immunotherapy agents in combination with radiation – this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumour shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumours.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumours. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.

Explore further: Oxygen levels in tumours affect response to treatment

More information: "A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models." Adlard AL, et al. Int J Cancer. 2014 Jan 4. DOI: 10.1002/ijc.28711. [Epub ahead of print]

Related Stories

Oxygen levels in tumours affect response to treatment

November 7, 2013
(Medical Xpress)—The genetic make-up of a patient's tumour could be used to personalise their treatment, and help to decide whether they would benefit from receiving additional drugs as part of their radiotherapy programme, ...

Scientists explore promising new option for first line of attack in lymphoma

February 25, 2014
Follicular lymphoma is a type of non-Hodgkin's lymphoma– a blood cancer - that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage.

Scientists harness immune system to prevent lymphoma relapse

October 18, 2012
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.

Breaking down cancer's defense mechanisms

December 20, 2013
A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

Prognosis of tumors positive for human papilloma virus in head and neck cancers varies according to the site

April 6, 2014
Patients with cancer of the throat and who are positive for the Human Papilloma virus (HPV+) have a good prognosis, but until now the effect of being HPV+ on the prognosis of tumours located elsewhere in the head and neck ...

Simple protein test could improve prediction of survival rates for patients with head and neck cancer

January 24, 2014
(Medical Xpress)—Scientists from The University of Manchester – part of the Manchester Cancer Research Centre - used a simple protein test that could prove more useful in predicting survival chances for patients with ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.